

**APPLICANTS: Vickers et al.**  
**SERIAL NO: 10/664,639**

**DOCKET NO: CORE0027US**

### **REMARKS**

Claims 1-9, 18-26, 29-34, 50, 51, 56-60, 63, 69-75, 77 and 79-107 are pending in the instant application. An Office Action has restricted the pending claims into the following groups:

Group I: Claims 1, 3, 4, 6-9, 18-26 and 29-34, drawn to methods of identifying a multi-functional oligomeric compound to modulate expression of RNA wherein the target region is identified by a single stranded oligomeric gene walk;

Group II: Claims 1, 3, 5-9, 18-26 and 29-34, drawn to methods of identifying a multi-functional oligomeric compound to modulate expression of RNA wherein the target region is identified by secondary structure analysis;

Group III: Claim 2, drawn to a multi-functional oligomeric compound;

Group IV: Claim 50, drawn to a method of selecting a single stranded oligomeric compound comprising contacting a target RNA with one or more double stranded oligomeric compounds;

Group V: Claim 51, drawn to a method of selecting a double stranded oligomeric compound comprising contacting a target RNA with one or more single stranded oligomeric compounds;

Group VI: Claims 56-60, 63, 69-75, 77 and 79-84, drawn to siRNA oligomeric compounds;

Group VII: Claims 85-99, drawn to methods of eliciting cleavage of a target mRNA in a cell; and

Group VIII: Claims 100-107, drawn to antisense oligomeric compounds.

Applicants elect Group VII, claims 85-99, without traverse. Applicants have canceled Group(s) I-VI and VIII, claim(s) 1-9, 18-26, 29-34, 50, 51, 56-60, 63, 69-75, 77, 79-84 and 100-107 as required by the restriction response. However, Applicants reserve the right to pursue the matter in a divisional application.

The Office Action further requires Applicants to elect a single target gene and target region. In a telephone conference with Applicants' representative Jodi Connolly on June 21, 2006, the Examiner confirmed election of a target gene and target region is NOT required with the election of Group VII. Therefore, Applicants believe a full and complete response to

**APPLICANTS: Vickers et al.**  
**SERIAL NO: 10/664,639**

**DOCKET NO: CORE0027US**


the restriction requirement has been provided.

Specification paragraph [000197] is amended herein to correct an obvious grammatical error and to clarify that the compound represented by ISIS 316449 comprises three 2'-O-methyl modifications on the 3' end. Table VI following paragraph [000202] clearly shows ISIS 316449 contains 2'-O-methyl modifications (bold italicized residues). 2'-O-methyl modification of ISIS 316449 is further confirmed in paragraph [000209]. No new matter has been added to the specification.

It is believed that no fee is due with this response. However, if a fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account 50-0252, referencing the above named application.

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early Office Action on the merits of the case is respectfully requested.

Respectfully submitted,

  
Jodi L. Connolly, Ph.D.  
Registration No. 54,044

Date: 06/30/2006

ISIS Pharmaceuticals, Inc.  
1896 Rutherford Rd.  
Carlsbad, CA 92008  
Telephone: (760) 603-2777  
Facsimile: (760) 603-3820